Table 1.
Meta-analysis of the APOB rs693 polymorphism with plasma APOB and lipid levels
| Groups or subgroups | Comparisons (Subjects) | P Heterogeneity | SMD (95% CI) | P SMD |
|---|---|---|---|---|
| APOB | ||||
| All | 63 (12,364) | < 0.01 | 0.26 (0.16–0.36) | < 0.01 |
| Studies in HWE | 53 (10,818) | < 0.01 | 0.25 (0.14–0.36) | < 0.01 |
| Male | 14 (2620) | 0.13 | 0.12 (0.01–0.24) | 0.03 |
| Female | 7 (1014) | 0.37 | 0.29 (0.12–0.45) | < 0.01 |
| Caucasian | 21 (5512) | < 0.01 | 0.19 (0.08–0.30) | < 0.01 |
| Asian | 38 (6129) | < 0.01 | 0.34 (0.16–0.51) | < 0.01 |
| CHD | 9 (1198) | 0.03 | 0.17 (−0.05–0.38) | 0.12 |
| Healthy or control | 39 (8829) | < 0.01 | 0.25 (0.12–0.38) | < 0.01 |
| Case-control studies | 34 (4971) | < 0.01 | 0.15 (0.05–0.25) | < 0.01 |
| Cohort studies | 29 (7393) | < 0.01 | 0.41 (0.24–0.57) | < 0.01 |
| TG | ||||
| All | 85 (22,128) | < 0.01 | 0.12 (0.05–0.20) | < 0.01 |
| Studies in HWE | 71 (19,590) | < 0.01 | 0.13 (0.05–0.21) | < 0.01 |
| Male | 19 (2867) | 0.05 | 0.00 (−0.12–0.11) | 0.95 |
| Female | 8 (1077) | 0.65 | 0.10 (−0.05–0.25) | 0.19 |
| Caucasian | 26 (5454) | 0.14 | 0.02 (−0.06–0.10) | 0.65 |
| Asian | 47 (14,257) | < 0.01 | 0.25 (0.12–0.37) | < 0.01 |
| CHD | 14 (1716) | < 0.01 | 0.11 (−0.09–0.30) | 0.28 |
| Healthy or control | 50 (17,429) | < 0.01 | 0.09 (0.00–0.18) | 0.04 |
| Case-control studies | 49 (6571) | < 0.01 | 0.11 (0.00–0.23) | 0.05 |
| Cohort studies | 36 (15,557) | < 0.01 | 0.13 (0.03–0.22) | 0.01 |
| TC | ||||
| All | 98 (41,764) | < 0.01 | 0.24 (0.17–0.30) | < 0.01 |
| Studies in HWE | 80 (30,373) | < 0.01 | 0.26 (0.18–0.34) | < 0.01 |
| Male | 22 (3594) | 0.18 | 0.14 (0.05–0.22) | < 0.01 |
| Female | 12 (1362) | < 0.01 | 0.14 (−0.09–0.37) | 0.22 |
| Caucasian | 38 (32,268) | < 0.01 | 0.14 (0.09–0.20) | < 0.01 |
| Asian | 48 (7080) | < 0.01 | 0.45 (0.25–0.66) | < 0.01 |
| CHD | 17 (2076) | 0.34 | 0.13 (0.03–0.24) | 0.01 |
| Healthy or control | 52 (10,745) | < 0.01 | 0.28 (0.14–0.41) | < 0.01 |
| Case-control studies | 51 (6734) | < 0.01 | 0.19 (0.10–0.28) | < 0.01 |
| Cohort studies | 47 (35,030) | < 0.01 | 0.29 (0.19–0.38) | < 0.01 |
| LDL-C | ||||
| All | 82 (22,286) | < 0.01 | 0.22 (0.14–0.30) | < 0.01 |
| Studies in HWE | 67 (19,724) | < 0.01 | 0.25 (0.16–0.34) | < 0.01 |
| Male | 18 (2685) | 0.83 | 0.18 (0.10–0.27) | < 0.01 |
| Female | 9 (1138) | < 0.01 | 0.05 (−0.23–0.33) | 0.72 |
| Caucasian | 26 (5893) | 0.04 | 0.17 (0.08–0.26) | < 0.01 |
| Asian | 46 (14,268) | < 0.01 | 0.33 (0.19–0.48) | < 0.01 |
| CHD | 13 (1624) | 0.03 | 0.07 (−0.09–0.24) | 0.38 |
| Healthy or control | 48 (17,243) | < 0.01 | 0.23 (0.13–0.33) | < 0.01 |
| Case-control studies | 42 (5871) | < 0.01 | 0.14 (0.05–0.24) | < 0.01 |
| Cohort studies | 40 (16,415) | < 0.01 | 0.31 (0.19–0.44) | < 0.01 |
| HDL-C | ||||
| All | 81 (39,292) | < 0.01 | −0.06 (−0.11–0.01) | 0.01 |
| Studies in HWE | 66 (28,316) | < 0.01 | −0.04 (−0.10–0.01) | 0.12 |
| Male | 19 (2912) | 0.03 | −0.08 (−0.19–0.03) | 0.17 |
| Female | 8 (1079) | 0.54 | −0.02 (−0.17–0.14) | 0.84 |
| Caucasian | 26 (30,367) | 0.05 | −0.04 (−0.08–0.01) | 0.11 |
| Asian | 45 (6748) | < 0.01 | −0.08 (−0.19–0.02) | 0.12 |
| CHD | 13 (1665) | 0.02 | −0.15 (−0.32–0.01) | 0.07 |
| Healthy or control | 46 (9700) | < 0.01 | −0.03 (−0.11–0.05) | 0.49 |
| Case-control studies | 43 (6020) | < 0.01 | −0.05 (−0.14–0.04) | 0.29 |
| Cohort studies | 38 (33,272) | < 0.01 | −0.06 (−0.11–0.00) | 0.04 |
SMD standardized mean difference, 95% CI 95% confidence interval, HWE Hardy-Weinberg equilibrium, APOB apolipoprotein B, TG triglyceride, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol